1. INTRODUCTION {#sec1}
===============

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most commonly diagnosed subtypes of non-Hodgkin lymphoma (NHL) in the United States. The established prognostic factors for DLBCL as delineated in the International Prognostic Factor Index (IPI) include age, clinical stage, number of extranodal sites, performance score, and lactate dehydrogenase level \[[@B1]\]; the established prognostic factors for FL as validated by the Follicular Lymphoma International Prognostic Index (FLIPI) include age, clinical stage, number of nodal areas, hemoglobin level, and lactate dehydrogenase level \[[@B2]\]. However, the clinical course of both diseases is variable, and both IPI and FLIPI predict prognosis incompletely. Patient genetic variation may improve predicted prognosis after diagnosis with DLBCL and FL.

Genetic variation in the 6p21 chromosomal region has been linked to both etiology and clinical courses of lymphomas and related risk factors. The 6p21 chromosomal region houses the major histocompatibility complex, which includes the human leukocyte antigen (*HLA*) genes and tumor necrosis factor (*TNF*). *TNF*and the ancestral *HLA* haplotype 8.1, which includes *TNF,* (AH 8.1: *HLA A\*01-B\*08-DRB1\*03-TNF-308A*) have been implicated in DLBCL etiology in epidemiology studies \[[@B3]\] and NHL survival in a series of clinical studies \[[@B4]--[@B7]\]. In our etiological investigations, we have also reported associations between *HLA-DRB1\*04:01* with DLBCL risk and *HLA-DRB1\*13* and*HLA-DRB1\*01:01* with FL risk \[[@B8]\], the latter of which has been corroborated in a genome-wide association study (GWAS) \[[@B9]\]. In addition, all *HLA-B* alleles can be further grouped (mutually exclusively) as *HLA-B Bw4* or *Bw6* based on amino acid residues at positions 79--83, and *HLA-B Bw4* has been associated with and has delayed progression to acquired immunodeficiency syndrome (AIDS) among those with the human immunodeficiency virus (HIV), a known risk factor for NHL \[[@B10]\].

Here, we evaluate whether these previously implicated alleles, other *HLA* class I (A, B, C) and class II *DRB1* alleles, and AH 8.1 are associated with DLBCL and FL survival in a multicenter population-based study of NHL in the United States.

2. METHODS {#sec2}
==========

Details of the National Cancer Institute-Surveillance, Epidemiology and End Results (NCI-SEER) NHL population-based case-control study have been described elsewhere \[[@B4], [@B8], [@B11]\]. Briefly, 1,321 newly diagnosed and histologically confirmed NHL patients, aged 20--74 years, were identified in four SEER registries (Iowa; Detroit, Mich; Los Angeles, Calif; Seattle, Wash) during July 1998--June 2000. Patients had no evidence of HIV infection but testing for HIV was not conducted as part of the study. All participants provided written informed consent and completed an in-person interview; 1172 (89%) provided either a venous blood sample (*n* = 773) or mouthwash buccal cell sample (*n* = 399). Of 365 DLBCL (215 with blood) and 278 FL (192 with blood) cases enrolled in the study, the present analysis comprises the 179 DLBCL and 180 FL cases who had complete clinical and demographic information and sufficient DNA for *HLA* allelotyping. Characteristics for those with sufficient DNA and those without sufficient DNA were similar (data not shown), making any potential biases for our results based on patients with sufficient DNA unlikely.

Demographic information, including age, sex, race, Hispanic ethnicity, and education level, was derived from patients\' interviews as part of the case-control study. Clinical information, including date of diagnosis, histology, stage, presence of B-symptoms, first course of therapy, date of last followup, and vital status, was derived from linkages to the SEER registry databases at each study site in 2008. Data on first course of therapy included use of single or multiagent chemotherapy, radiation, other therapies exclusive of chemotherapy and/or radiation, and no therapy (observation); information on individual agents and doses was not available. The SEER registries collect date and cause of death but do not collect data on treatment response or disease recurrence or progression.

Pathology information was derived from abstracted reports by the local diagnosing pathologist. All cases were coded according to the International Classification of Diseases-Oncology (ICD-O), 2nd Edition, and updated to the WHO/ICD-O-3. DLBCL was defined as ICD-O 9678, 9679, 9680, and 9684 and FL as 9690-9691, 9695, and 9698.

DNA was extracted using Puregene Autopure DNA extraction kits (Gentra Systems, Minneapolis, Minn). Four-digit *HLA* Class I (A, B, and C) and Class II genotyping (*DRB1*) was conducted at NCI-Frederick (Frederick, MD) according to sequence-specific oligonucleotide probe (SSOP) hybridization and sequence-based typing protocols developed by the 13th International Histocompatibility Workshop. Agreement for quality control duplicates (*n* = 100) was ≥99%. *HLA* alleles were defined as presence (if the individual had either one or two copies of the allele) or absence of the specific allele (defined as having no copies of the allele). *TNF* genotyping was conducted at the National Cancer Institute Core Genotying facility (Gaithersburg, MD, USA) using the Taqman (Foster City, Calif, USA) PLATFORM. *TNF G-308A*was defined by genotype (GG (referent), GA, and AA). Haplotypes for *HLA-A-B-DR* were determined using "FastHap", which determines haplotypes by expectation maximization (<http://home.ncifcrf.gov/ccr/lgd/bioinformatics/index_n.asp>).

We fit Cox proportional hazard regression models to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the association of each individual *HLA* loci (e.g., *HLA-A*, *-B*, *-C,*or*-DRB1*) and haplotype with overall survival, adjusting for demographic and clinical factors. Demographic and clinical factors were modeled as one risk score, which was a linear combination of age (\<60 versus ≥60 years), sex, race (white and all other), study center (Detroit, Iowa, Los Angeles, and Seattle), and years of education (\<12, 12--15, and ≥16 years), tumor stage (local, regional, distant, and missing), presence of B symptoms (no, yes, missing), and type of initial therapy (chemotherapy plus radiation, chemotherapy plus other therapy, radiation only, all other, or missing therapy) \[[@B4], [@B11]\]. Analyses were also conducted restricted to non-Hispanic Caucasians. Two-sided *P* values were reported. All analyses were conducted using SAS 9.1.3 (SAS Institute, Cary, NC, USA).

3. RESULTS {#sec3}
==========

Descriptive characteristics (demographic and clinical features) of our population are shown in [Table 1](#tab1){ref-type="table"}. The median age at diagnosis was 58 years for DLBCL patients (range, 20--74) and 56 years for FL patients (range, 28--74) \[[@B8]\]. Male patients comprised 55% and 49% of DLBCL and FL, respectively. Ninety-two percent DLBCL and FL patients identified themselves as non-Hispanic Caucasians. Thirty-eight percent of DLBCL and 56% of FL patients had advanced stage (distant) disease. Twenty-four percent of DLBCL and 14% of FL patients had B symptoms. Chemotherapy-based regimen was the most common initial therapy. With a median followup of 89 months (range, 7--112 months), 58 of 179 (32%) DLBCL and 48 of 180 (27%) FL patients died.

HLA Class I and II AllelesAmong FL cases, presence of *HLA-A\*01:01* was associated with poorer OS (HR = 2.23, 95% CI = 1.24--4.01), whereas the presence of *HLA-B Bw4* (HR = 0.36, 95% CI = 0.20--0.63) and *HLA-DRB1\*13* (HR = 0.12, 95% CI = 0.02--0.90) was associated with better OS ([Table 2](#tab2){ref-type="table"}). The presence of *HLA-Cw\*07:01* was associated with poorer OS among DLBCL patients (HR = 1.76, 95% CI = 1.01--3.05).

AH 8.1The AH 8.1 (*HLA-A\*01-B\*08-DR\*03-TNF-308A*) was associated with poorer OS among patients with FL, likely due to a strong association with the *HLA-A\*01-B\*08-DR\*03* haplotype (HR = 2.19, 95% CI = 1.08--4.45), whereas *TNF*G-308A was not associated with survival after FL ([Table 2](#tab2){ref-type="table"}). In contrast, among patients with DLBCL, the AH 8.1 and HLA-A were not associated with OS, but the presence of the *TNF-308A*allele was associated with poorer OS (HR for GA/AA versus GG = 1.79, 95% CI = 1.02--3.14).

Corresponding survival curves for each HLA allele and AH 8.1 association for DLBCL and FL are shown in the [Figure 1](#fig1){ref-type="fig"}.

4. DISCUSSION {#sec4}
=============

Our data suggest that specific *HLA* alleles are associated with survival among DLBCL and FL patients. Specifically, *HLA-Cw\*07:01* was associated with poorer OS among DLBCL patients, and *HLA-A\*01:01*was associated with poorer OS and *HLA-DRB1\*13*and *HLA-B Bw4* with better OS among FL patients. Overall, the results add to the growing body of evidence of a role for *HLA* in the prognosis of these subtypes.

Our results agree with various clinical studies \[[@B5]--[@B7], [@B12]\] in which *TNF G-308A* and AH 8.1 have been reported to influence clinical course and outcome of NHL overall. In one analysis restricted to DLBCL patients, TNF-*α* in plasma predicted DLBCL survival \[[@B12]\], a pattern consistent with our study results that *TNF* G-308A increases the risk of death among DLBCL patients. In that study, the authors also reported that AH 8.1 predicted overall survival of NHL patients, and that *HLA-A\*01* and *HLA-B\*08* were associated with prognosis \[[@B7]\]. In this study, AH 8.1 was associated with poorer OS among FL patients, a result that our data suggest to be largely driven by the association with *HLA-A\*01:01.* Taken together, our results support the hypothesis that chronic inflammation contributes to poorer prognosis of DLBCL, but other mechanisms of immune dysregulation may further be considered for FL prognosis.

We previously reported that the*HLA-DRB1\*13* group of alleles were associated with decreased risk of developing FL. The newly identified association with better survival, if confirmed in other data, would implicate an important *HLA* allele in both FL etiology and survival. We also found better OS among FL patients with *HLA-B Bw4*, suggesting possible similarities in mechanisms by which *HLA-B Bw4* slows the progression to AIDs. On the other hand, we did not observe a joint relationship between *HLA-B Bw4* with the KIR receptor (*KIR3DS1*), as has been reported for AIDS outcomes (data not shown) \[[@B10]\]. These results support the potential role for the innate immune response and immune surveillance as important aspects for FL etiology and prognosis.

We also report here that *HLA-Cw\*07:01*was associated with poorer OS among DLBCL patients, which was not found in a previous study \[[@B7]\]. This inconsistency could reflect chance, heterogeneity of the NHL definition in the previous clinical studies where the authors examined the risk of NHL overall instead of by subtype \[[@B5]--[@B7]\], or dilution of the moderate association in the broad NHL definition compared to analysis specific to DLBCL.

We note that most of of the *HLA* alleles identified as potentially relevant for etiology were not predictive for survival, suggesting distinct functions for these genetic variations \[[@B8]\]. Alleles previously found associated with NHL etiology in our study included *HLA-A\*26:01, A\*29:02, B\*51:01, Cw\*03:04, Cw\*15:02, DRB1\*04:01, and HLA-DRB1\*01:01* \[[@B8]\], none of which were identified as associated with survival after DLBCL or FL.

An important strength of our study was the population-based ascertainment of newly diagnosed cases, making our results more applicable to community-based treatment programs. Furthermore, we were able to evaluate the results by subtype, whereas most clinical studies have only assessed the association for NHL overall \[[@B5]--[@B7]\]. One important potential limitation apart from sample size is the lack of detailed data on prognostic factors or treatment and that we missed most DLBCL deaths that occurred in the first year. By using age, stage, B symptoms, and treatment class, we, nonetheless, could predict survival with a level of ability similar to the IPI for a large study of DLBCL and FL patients \[[@B4], [@B11]\]. Because all patients were initially treated before the widespread use of rituximab, it will be important to evaluate a patient population treated with rituximab alone (for both DLBCL and FL) and in combination with CHOP chemotherapy (for DLBCL).

In summary, our results support a role for *HLA* in overall survival of DLBCL and FL patients, after accounting for demographic and clinical factors. Our results are consistent with the emerging significance of the complex host genetic background in progression of each NHL subtype. Host immunogenetics, particularly the major histocompatibility region that houses a number of immune genes including *HLA*, represent a promising class of prognostic factors that warrant further evaluation.
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###### 

Survival curves and Kaplan-Meier *P*-values among patients with DLBCL and FL by HLA alleles and haplotype: (a) *AH 8.1*; (b) *HLA-DRB1\*13*; (c) *HLA-Bw4*; (d) *HLA-A\*01:01*; (e) *HLA-Cw07:01*.
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###### 

Demographic and clinical characteristics of DLBCL and FL patients from the NCI-SEER NHL study for which HLA typing was conducted.

  Characteristics            DLBCL        FL
  -------------------------- ------------ ------------
  *Sex*                                   
   Male                      99 (55.3)    89 (49.4)
   Female                    80 (44.7)    91 (50.6)
  *Age (years)*                           
   \<60                      93 (52.0)    103 (57.2)
   60+                       86 (48.0)    77 (42.8)
  *Race*                                  
   Non-Hispanic Caucasian    165 (92.2)   165 (91.7)
   Other                     14 (7.8)     15 (8.3)
  *Study Center*                          
   Detroit                   19 (10.6)    16 (8.9)
   Iowa                      67 (37.4)    76 (42.2)
   Los Angeles               29 (16.2)    30 (16.7)
   Seattle                   64 (35.8)    58 (32.2)
  *Education (years)*                     
   \<12                      16 (8.9)     11 (6.1)
   12--15                    118 (65.9)   118 (65.6)
   16+                       45 (25.1)    51 (28.3)
  *Stage*                                 
   Local                     69 (38.6)    44 (24.4)
   Regional                  39 (21.8)    25 (13.9)
   Distant                   38 (38.0)    101 (56.1)
   Unknown                   3 (1.7)      10 (5.6)
  *Presence of B symptoms*                
   No                        136 (76.0)   154 (85.6)
   Yes                       43 (24.0)    26 (14.4)

###### 

*HLA* class I and II alleles and haplotypes and their associations with overall survival among diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients.

                                             DLBCL   FL                                                                 
  --------------------------------- -------- ------- ----------------------- ------------ ----- ----------------------- ------------
  *HLA class I*                                                                                                         
   *HLA-A\*01:01*                   Absent   107     31                      1.00 (ref)   109   23                      1.00 (ref)
  Present                           59       21      1.30 (0.74--2.26)       54           22    **2.23 (1.24--4.01)**   
  * HLA-B\*08:01*                   Absent   123     35                      1.00 (ref)   123   32                      1.0 (ref)
  Present                           42       17      1.40 (0.78--2.51)       42           14    1.39 (0.74--2.61)       
  * HLA-Cw\*07:01*                  Absent   111     28                      1.00 (ref)   116   32                      1.00 (ref)
  Present                           55       24      **1.76 (1.01--3.05)**   49           14    1.12 (0.60--2.10)       
  * HLA-B Bw4*                      Absent   73      27                      1.00 (ref)   55    25                      1.00 (ref)
  Present                           106      31      0.97 (0.58--1.64)       125          23    **0.36 (0.20--0.63)**   
                                                                                                                        
  *HLA class II*                                                                                                        
  * HLA-DRB1\*01:01*                Absent   134     43                      1.00 (ref)   118   32                      1.00 (ref)
  Present                           32       9       0.94 (0.46--1.94)       47           14    1.12 (0.59--2.10)       
  * HLA-DRB1\*03:01*                Absent   121     34                      1.00 (ref)   127   33                      1.00 (ref)
  Present                           45       18      1.41 (0.79--2.50)       38           13    1.33 (0.70--2.54)       
  * HLA-DRB1\*13*                   Absent   137     39                      1.00 (ref)   146   47                      1.00 (ref)
  Present                           29       13      1.34 (0.71--2.55)       19           1     **0.12 (0.02--0.90)**   
                                                                                                                        
  *AH 8.1*                                                                                                              
  * HLA-A\*01-B\*08-DR\*03*         Absent   135     40                      1.00 (ref)   143   35                      1.00 (ref)
  Present                           30       12      1.46 (0.76--2.80)       20           10    **2.19 (1.08--4.45)**   
  * TNF G-308A*                     GG       98      26                      1.00 (ref)   107   28                      1.00 (ref)
  GA                                53       21      1.66 (0.93--2.97)       42           15    1.52 (0.81--2.86)       
  AA                                6        3       **3.81 (1.13--12.9)**   4            1     0.84 (0.11--6.19)       
  GA/AA                             59       24      **1.79 (1.02--3.14)**   46           16    1.45 (0.78--2.68)       
  * HLA-A\*01-B\*08-DR\*03-TNF-A*   Absent   132     39                      1.00 (ref)   135   34                      1.00 (ref)
  Present                           29       11      1.39 (0.71--2.73)       20           10    **2.13 (1.05--4.34)**   

All models adjusted for the risk score that combined both demographic and clinical information.

The total numbers for each allele may differ due to laboratory interpretation of each allele which was done individually (e.g., ambiguous results for each allele were excluded from analysis rather than presumed to be absent).
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